L-Arginine HCl (L-Arg)
For research use only.
CAS No. 1119-34-2
L-Arginine is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.
Purity & Quality Control
Choose Selective NOS Inhibitors
|Description||L-Arginine is the nitrogen donor for synthesis of nitric oxide, a potent vasodilator that is deficient during times of sickle cell crisis.|
L-Arginine (0.3 mM, 30 minutes) supplementation do not induce any significant increases in the peak NO concentration at low level of native LDL. However, at native LDL concentrations from 60-130 mg cholesterol/dL, NO concentration is 2 times higher than before L-Arginine treatment in bovine aortic endothelial cells. L-Arginine (0.3 mM, 30 minutes) pretreatment results in a significant increase of NO production in n-LDL–treated cells as well as in oxidized -LDL–treated cells in bovine aortic endothelial cells. L-Arginine (0.3 mM, 30 minutes) does not increase O2- concentration at low nativeLDL concentrations but reduce O2- production by 50% when incubate with n-LDL at concentrations >40 mg cholesterol/dL in bovine aortic endothelial cells. L-Arginine (0.3 mM, 30 minutes) pretreatment completely abolishes O2- production at every oxidized LDL dosage in bovine aortic endothelial cells. 
|In vivo||L-Arginine (4 mg/kg/min for 1 hour) treatment decreases superoxide generation by cNOS while increasing NO accumulation in rabbit limb during ischemia/reperfusion. L-Arginine (4 mg/kg/min for 1 hour) prevents microvessel constriction in the reperfused muscle despite reduced but still apparent interstitial edema in rabbit limb. L-Arginine (4 mg/kg/min for 1 hour) treatment results in a significant reduction of muscular reperfusion edema in rabbit limb.  L-Arginine (0.1 g/kg, oral) supplementation significantly reduces pulmonary artery systolic pressure by a mean of 15.2% after 5 days of therapy in patients with sickle cell disease. Both L-Arginine and ornithine concentrations increased significantly after 5 days of oral L-Arginine (0.1 g/kg) supplementation in patients with sickle cell disease.  L-Arginine is associated with a decrease in cardiac index while stroke index is maintained in patients with severe sepsis. Resolution of shock at 72 hours is achieved by 40% and 24% of the patients in the L-Arginine and placebo cohorts, respectively.  L-Arginine (450 mg/kg during a 15-minute period) amplifies and sustains the hyperemia (38%) and increases absolute brain blood flow after eNOS upregulation by chronic simvastatin treatment (2 mg/kg subcutaneously, daily for 14 days) in SV-129 mice. |
-  Vergnani L, et al. Circulation, 2000, 01(11), 1261-1266.
-  Huk I, et al. Circulation, 1997, 96(2), 667-675.
-  Morris CR, et al. Am J Respir Crit Care Med, 2003, 168(1), 63-69.
|In vitro||Water||42 mg/mL (199.37 mM)|
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
In vivo Formulation Calculator (Clear solution)
|Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)|
|Dosage||mg/kg||Average weight of animals||g||Dosing volume per animal||ul||Number of animals|
|Step 2: Enter the in vivo formulation ()|
|% DMSO % % Tween 80 % ddH2O|
Working concentration： mg/ml；
Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL，)
Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH2O，mix and clarify.
1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT04456491||Not yet recruiting||--||Asthma|COPD||Ryazan State Medical University||July 1 2021||--|
|NCT04535427||Not yet recruiting||Drug: L-arginine|Drug: Placebo||Rheumatoid Arthritis||RenJi Hospital||January 1 2021||Phase 2|
|NCT04328311||Active not recruiting||Other: Watermelon Juice|Other: Water||Healthy Aging||University of Reading||January 8 2020||Not Applicable|
|NCT04156711||Recruiting||Procedure: Remote Ischemic Preconditioning (RIPC)||Acute Cholecystitis|Endothelial Dysfunction||Zealand University Hospital||September 4 2019||Not Applicable|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.